Erik Lundström

adjunct senior lecturer at Department of Neuroscience, Landtblom: Neurology

Visiting address:
Akademiska sjukhuset
Postal address:
Akademiska sjukhuset
751 85 UPPSALA

consultant at Department of Neuroscience, Landtblom: Neurology

Visiting address:
Akademiska sjukhuset
Postal address:
Akademiska sjukhuset
751 85 UPPSALA

Short presentation

Vision for science
Stroke research that matters.

Vision as a leader
Inject people with passion.

I'm the Chief Investigator of the EFFECTS (Efficacy of Fluoxetine – a randomised controlled trial in stroke) trial. You can subscribe to our electronic letter. It's free and will always be free. We will not share your private information. You're welcome to connect with me on TWITTER and Facebook.

Keywords: stroke akut neurologi neurology fluoxetine plasticity randomised controlled trial rct

My courses


Current position

  • Consultant Neurology at Uppsala University Hospital and clinical lead for the stroke unit. Ongoing (since April 2018).
  • Senior lecturer of Neurology at Department of Neuroscience, Uppsala University. Ongoing (since July 2018).
  • Chief Investigator of EFFECTS, the largest randomised controlled stroke study in Sweden.
    Supported by the Swedish Research Council (Vetenskapsrådet), the Swedish Brain Foundation,(Hjärnfonden), the Swedish Heart-Lung Foundation (Hjärt- Lungfonden), the Swedish Society of Medicine (Svenska Läkaresällskapet), the Swedish Stroke Association (Stroke Riksförbundet), King Gustav V and Queen Victorias Foundation of Freemasons, Karolinska Institutet, and Uppsala University. All funders are non-commercial. None of the funders have any influence on the planning, conduct or interpretation of the study.
  • EFFECTS is an academic initiated, investigated led multicentre, parallel group, randomised, placebo-controlled trial of fluoxetine for stroke recovery.
    We investigate whether routine administration of fluoxetine 20mg once daily in the 6 months after an acute stroke improves the patient’s functional outcome.

Medical degrees

  • Associate Professor of Neurology at Karolinska Institutet. 2017.
  • Dissertation at Uppsala University, Sweden, Inst f Neuroscience, Neurology and rehabilitation medicine. Spasticity after first-ever stroke. 2009.
  • Medical Degree at Uppsala University. 1993.

Supervision for PhD students

  • Co-supervisor of Svante Wallmark, at Uppsala University, Department of Neuroscience, Neurosurgery. Dr Wallmarks thesis studied the effects of subarachnoid haemorrhage, including cognitive impairment, and defended his thesis Life after subarachnoid haemorrhage 17/01/2017.
  • Supervisor of Ann-Sofie Rudberg and Eva Isaksson, both at Karolinska Institutet.
    Dr Rudberg's projects will investigate long-term survival, health-related quality of life and cost aspects associated with stroke treatment, and will be based on two clinical stroke studies: IST-3 and EFFECTS. Ongoing.
    Eva Isaksson's thesis aims to describe factors that contribute to successful recruitment in a randomised controlled trial. Ongoing.
  • Co-supervision for Melinda Berg Roaldsen, PhD student at UiT The Arctic University of Norway (ongoing). Roaldsen's research focuses on thrombolytic treatment of acute ischaemic stroke with a special emphasis on wake-up stroke. She is currently the international Trial Manager of the randomised-controlled trial TWIST (Tenecteplase in Wake-up Ischaemic Stroke Trial). Ongoing,

Supervision of students

  • 10 students at Uppsala University, Medicine Programme, student thesis, 5 x 30 hp, 5 x 5 hp
  • 1 student at Karolinska Institutet, Medicine Programme, 30 hp
  • 1 student at Gothenburg University, Pharmacy Programme, 30 hp


  • Extensive teaching (> 400 h) for medical students, physiotherapists and nurses at Uppsala University. Also taught at the physiotherapist-, speech therapy- and at biomedical analysts-programme, Uppsala University.
    Some teaching at the medical programme, Karolinska Institutet.

Clinical experience since 2005

  • Consultant Neurology and Medically responsible doctor for the stroke unit at Karolinska University Hospital, Solna. Between December 2012 and Mars mars 2018.
  • Consultant Neurology, Uppsala University Hospital. 2012.
  • Specialist in neurology Uppsala University Hospital and specialist examination in Neurology 2005.


This is a compressed and adapted research plan of EFFECTS (date 12/NOV/2017), the full protocol and amendments are available here. The text is similar to the one at the EFFECTS homepage.

Purpose of the project

The purpose is to find a new treatment for stroke recovery. The aim is to test whether an established drug against depression (Fluoxetine) can improve recovery and quality of life after stroke.

Expected results and benefits for individuals and society

The expected results are better functioning and improved quality of life.

Fluoxetine is inexpensive (only 300 SEK for 6 months’ treatment), simple to administer and generally well tolerated. If it proves effective, it can be implemented when the study is completed, in 2020. It could be available to a wide range of stroke patients, both ischemic and haemorrhagic stroke, and even in low to middle-income countries.

The project’s originality and novelty

  1. We are studying a new mechanism for stroke, selective serotonin re-uptake inhibitors (SSRI), for stroke recovery. We want to test whether routine administration of Fluoxetine (20 mg once daily) in the 6 months after an acute stroke improves the patient’s functional outcome.
  2. An academic-initiated, investigator-led, randomised controlled study (RCT).
  3. We aim to include 1,500 patients in Sweden, making EFFECTS the largest RCT study of stroke in Sweden.
  4. A collaboration with FOCUS and AFFINITY, two other international, investigator-led studies, with the same inclusion and exclusion criteria. A meta-analysis of individual patient data is planned.
  5. It has a pragmatic design, that is we investigate if the interventions work in normal practice, with fewer selected patients and a flexible intervention applied as it would be in normal practice, and finally, outcomes that are relevant to patients and society.
  6. The study includes both ischemic and haemorrhagic stroke.
  7. Fluoxetine is inexpensive (only 300 SEK for 6 months’ treatment), simple to administer, and generally well tolerated. If it proves effective, it can be implemented quickly in the healthcare system.
  8. Good track record regarding data quality and inclusion. Reassuringly, we randomise 35 patient per month. We have included almost 1,200 patients.


Please contact the directory administrator for the organization (department or similar) to correct possible errors in the information.